Table 1.

Screening Pubmed for NMOSD cohorts and case reports with at least 1 patient with onset >60 years did not reveal patients at least as old as our NMOSD patient with very late-onset at 88 years. Onset >50 years is usually defined already as late-onset

Location/ethnicity (age limit for study inclusion)	Number of patients	Max. onset (age in years)	Clinical characteristics	References
Korea (–)	92	63	Patients with onset >50 year (22 %): more often myelitis onset and higher ARR	[7]
France, 87 % Caucasian (–)	125	66	20 % onset >50 year	[12]
Anglo-Saxon Americans and Hispanic Americans (–)	8	73	Oldest patient with ON onset. No LTI, relapse after 4 months, fatal course	[13] (before AQP4-Ab)
Australia (–)	71	79.6	Patients with onset >50 year: less often optic neuritis onset	[9]
Europe, 93 % Caucasian (late-onset NMOSD >50 year)	108	82.5	Myelitis onset in 67 %. Mean follow-up 4.6 year, 82 % with relapses	[6]
Japan (–)	583	86	Patients with onset >60 year: more often myelitis onset	[8]
Italy (late-onset case report)	1	64	Optic neuritis and myelitis onset. Two relapses within months, fatal course	[14] (before AQP4-Ab)
USA (late-onset case report)	1	69	Optic neuritis and myelitis onset	[15] (before AQP4-Ab)
France (late-onset case report)	1	77	Myelitis onset. W/o LTI, relapse after 1 year	[16]
USA (late-onset case report)	1	81	Brainstem and myelitis onset. No LTI, several relapses and death within about 1 year	[17] (before AQP4-Ab)
USA (late-onset case report)	1	85	Myelitis onset, no long-term follow-up	[18]

ARR annualized relapse rate, before AQP4-Ab study performed before availability of AQP4-Ab testing, LTI long-term immuno-suppressive therapy